These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32896220)

  • 1. The future of research into genetics and the precision dosing of tacrolimus: what do we need to know?
    Zhu J; Pasternak AL; Crona DJ
    Pharmacogenomics; 2020 Oct; 21(15):1061-1064. PubMed ID: 32896220
    [No Abstract]   [Full Text] [Related]  

  • 2. "What do we know about tacrolimus pharmacogenetics in transplant recipients?".
    Kuypers DR
    Pharmacogenomics; 2018 May; 19(7):593-597. PubMed ID: 29701126
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
    Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
    Birdwell KA; Decker B; Barbarino JM; Peterson JF; Stein CM; Sadee W; Wang D; Vinks AA; He Y; Swen JJ; Leeder JS; van Schaik R; Thummel KE; Klein TE; Caudle KE; MacPhee IA
    Clin Pharmacol Ther; 2015 Jul; 98(1):19-24. PubMed ID: 25801146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms and individualized tacrolimus dosing.
    López-Montenegro Soria MA; Kanter Berga J; Beltrán Catalán S; Milara Payá J; Pallardó Mateu LM; Jiménez Torres NV
    Transplant Proc; 2010 Oct; 42(8):3031-3. PubMed ID: 20970601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: pharmacogenetics and molecular medicine: "so close and yet so far".
    Moore JH; Hwa J
    Curr Mol Med; 2014; 14(7):803-4. PubMed ID: 25109800
    [No Abstract]   [Full Text] [Related]  

  • 8. PACE Forward-Making Pharmacogenomics Testing Available for Real-Life Clinical Utility.
    Lazaridis KN
    Clin Pharmacol Ther; 2019 Jan; 105(1):42-44. PubMed ID: 30520030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and tacrolimus administration in stem cell transplantation.
    Patel JN; Hamadeh IS
    Pharmacogenomics; 2020 Apr; 21(6):419-426. PubMed ID: 32308133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.
    Wang P; Mao Y; Razo J; Zhou X; Wong ST; Patel S; Elliott E; Shea E; Wu AH; Gaber AO
    Pharmacogenomics; 2010 Oct; 11(10):1389-402. PubMed ID: 21047202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding and Preventing Adverse Effects of Tacrolimus Metabolization in Transplant Patients.
    Fröhlich E
    Curr Drug Metab; 2019; 20(13):1039-1040. PubMed ID: 30081785
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical implementation of pharmacogenetics.
    García-González X; Cabaleiro T; Herrero MJ; McLeod H; López-Fernández LA
    Drug Metab Pers Ther; 2016 Mar; 31(1):9-16. PubMed ID: 26751902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigene predictors of tacrolimus exposure in kidney transplant recipients.
    Pulk RA; Schladt DS; Oetting WS; Guan W; Israni AK; Matas AJ; Remmel RP; Jacobson PA;
    Pharmacogenomics; 2015 Jul; 16(8):841-54. PubMed ID: 26067485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics in the clinic.
    Relling MV; Evans WE
    Nature; 2015 Oct; 526(7573):343-50. PubMed ID: 26469045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics: personalizing pediatric heart transplantation.
    Van Driest SL; Webber SA
    Circulation; 2015 Feb; 131(5):503-12. PubMed ID: 25645611
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients].
    Zhu L; Song HT; Wang QH; Wu WZ; Yang SL; Tan JM
    Yao Xue Xue Bao; 2012 Jul; 47(7):878-83. PubMed ID: 22993851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
    Berger FA; Mulder MB; Ten Bosch-Dijksman W; van Schaik RHN; Coenen S; de Winter BCM
    Br J Clin Pharmacol; 2019 Aug; 85(8):1852-1854. PubMed ID: 31190414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.